News
January 22, 2021
Based on a scientifically solid proof of concept in dogs and cats, an international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding campaign set to launch within a month, and to become profitable within 36 months of raising funds.
November 10, 2020
CureLab is expanding its global presence with a new office from which it will base operations in the European Union; Ricarda Cramer joins as business development director
October 21, 2020
CureLab is expanding its global presence with a new office in the Gulf Cooperation Council (GCC) region; CureLab's partners in the region will test the efficacy of the company's DNA-based products against cancers and non-cancerous diseases of chronic inflammation
October 14, 2020
Former US Secretary of Veterans Affairs and internationally known healthcare industry leader to advise on partnerships for upcoming clinical trials and market entry strategy for CureLab’s Elenagen cancer therapy
October 5, 2020
Feedback from FDA was constructive and includes recommendations to test cumulative toxicity and clinical benefits progression; this has led the company to consider a shorter trial design for Phase II.
April 29, 2020
CureLab Oncology’s Dr. Alex Shneider Publishes Paper: Can Melatonin Reduce the Severity of COVID-19?
Melatonin may prevent the development of severe disease symptoms in coronavirus patients, reduce the severity of their symptoms, and/or reduce the immuno-pathology of coronavirus infection on patients’ health after the active phase of the infection is over
January 20, 2020
CureLab Oncology CEO Alex Shneider’s lament is a biopharma industry that exhibits little appetite for those discoveries made while coloring outside the lines